https://www.tdrf.org.tw/2020/06/16/safety02-37/
Of course 🌿—here’s a compact clinical table for pyridoxine (vitamin B6) in psychiatry and neuropsychiatry:
Pyridoxine (Vitamin B6) in Psychiatry – Quick Reference
|
Indication |
Mechanism |
Typical Dose |
|
Isoniazid-induced neurotoxicity (neuropathy, seizures, mood changes) |
Isoniazid inactivates B6; supplementation restores GABA and monoamine synthesis |
2550 mg/day (prophylaxis) |
|
Other drug-induced deficiency (hydralazine, cycloserine, penicillamine, levodopa without carbidopa) |
Same as above; prevents neuropathy and psychiatric symptoms |
25100 mg/day |
|
Tardive dyskinesia (adjunctive, experimental) |
High-dose B6 may enhance GABA synthesis and reduce oxidative stress |
3001200 mg/day (divided; under supervision) |
|
Mood, anxiety, PMS, irritability (adjunctive) |
Cofactor for serotonin, dopamine, norepinephrine synthesis |
50100 mg/day (often with other B-vitamins) |
|
Alcohol use disorder (with malnutrition) |
Corrects deficiency contributing to neuropathy, irritability, seizures |
50100 mg/day (part of B-complex/banana bag) |
|
Hyperhomocysteinemia (with B12/folate; depression, cognitive decline) |
Cofactor in homocysteine metabolism (transsulfuration pathway) |
50200 mg/day |
⚠️ Clinical note:
- Usual supplementation is 25–100 mg/day.
- High doses (>500 mg/day long-term) risk sensory neuropathy → so experimental TD protocols need careful monitoring.
Would you like me to also prepare a one-page PDF handout of this table (with a clean layout), so you can drop it straight into your seminar materials or keep it as a quick clinical reference?
